Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alternativeName |
SAR-245409
XL765 |
| gptkbp:CASNumber |
1224844-38-5
|
| gptkbp:clinicalTrialPhase |
Phase I/II
|
| gptkbp:developedBy |
gptkb:Sanofi
gptkb:Exelixis |
| gptkbp:hasInChIKey |
QZKQJQJQJQJQJQ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C23H21F3N6O2S
|
| gptkbp:hasSMILES |
CC1=NN(C2=CC=CC=C12)C3=NC4=C(N3)C=CC(=C4)S(=O)(=O)N
|
| gptkbp:hasUNII |
6Q1K1Q1K0K
|
| https://www.w3.org/2000/01/rdf-schema#label |
SAR245409
|
| gptkbp:indication |
gptkb:cancer
solid tumors hematologic malignancies |
| gptkbp:isApprovedDrug |
true
|
| gptkbp:mechanismOfAction |
PI3K/mTOR dual inhibitor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
25154815 |
| gptkbp:target |
gptkb:PI3K
gptkb:mTOR |
| gptkbp:bfsParent |
gptkb:XL518
|
| gptkbp:bfsLayer |
8
|